相似文献
1
Tumor antigen presentation: changing the rules.
Cancer Immunol Immunother. 1998 Apr;46(2):70-4. doi: 10.1007/s002620050463.
2
Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
Blood. 2005 Mar 15;105(6):2465-72. doi: 10.1182/blood-2004-08-3105. Epub 2004 Nov 16.
3
T cells work together to fight cancer.
Curr Biol. 1999 Sep 23;9(18):R695-7. doi: 10.1016/s0960-9822(99)80442-4.
4
Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
PLoS One. 2014 Apr 1;9(4):e93231. doi: 10.1371/journal.pone.0093231. eCollection 2014.
5
Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
J Immunol. 2006 Feb 1;176(3):1447-55. doi: 10.4049/jimmunol.176.3.1447.
6
Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine.
JCI Insight. 2019 Apr 23;5(11):127305. doi: 10.1172/jci.insight.127305.
7
cDC1 prime and are licensed by CD4 T cells to induce anti-tumour immunity.
Nature. 2020 Aug;584(7822):624-629. doi: 10.1038/s41586-020-2611-3. Epub 2020 Aug 12.
8
Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity.
J Invest Dermatol. 2006 Aug;126(8):1804-12. doi: 10.1038/sj.jid.5700335. Epub 2006 Apr 27.
9
The identification of cancer antigens: impact on the development of cancer vaccines.
Cancer J. 2000 Apr;6 Suppl 2:S142-9.
10
Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens.
Immunol Rev. 2002 Oct;188:65-80. doi: 10.1034/j.1600-065x.2002.18807.x.
引用本文的文献
1
The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma.
Natl Sci Rev. 2014 Jul 14;1(3):396-412. doi: 10.1093/nsr/nwu038.
2
Use of ultraviolet-light irradiated multiple myeloma cells as immunogens to generate tumor-specific cytolytic T lymphocytes.
J Immune Based Ther Vaccines. 2008 Apr 28;6:2. doi: 10.1186/1476-8518-6-2.
3
MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
Cancer Immunol Immunother. 2004 Jun;53(6):525-32. doi: 10.1007/s00262-003-0486-4. Epub 2004 Jan 17.
4
Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice.
Clin Exp Immunol. 2001 Nov;126(2):220-9. doi: 10.1046/j.1365-2249.2001.01689.x.
5
Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model.
Med Oncol. 1999 Dec;16(4):267-78. doi: 10.1007/BF02785873.
Zotero 插件